WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 326888
CAS#: 114432-13-2
Description: Fantofarone, also known as SR 33557, is a highly potent calcium channel antagonist representative of a new class of slow channel blockers. Fantofarone can significantly modify cardiac function and in particular, decrease MO2C consumption during periods of elevated heart rate. Fantofarone is able to induce submaximal peripheral vasodilating effects at doses that are devoid of any clinically significant cardiac effect.
MedKoo Cat#: 326888
Name: Fantofarone
CAS#: 114432-13-2
Chemical Formula: C31H38N2O5S
Exact Mass: 550.2501
Molecular Weight: 550.714
Elemental Analysis: C, 67.61; H, 6.96; N, 5.09; O, 14.53; S, 5.82
Synonym: SR 33557; SR-33557; SR33557; Fantofarone
IUPAC/Chemical Name: N-(3,4-dimethoxyphenethyl)-3-(4-((2-isopropylindolizin-1-yl)sulfonyl)phenoxy)-N-methylpropan-1-amine
InChi Key: ITAMRBIZWGDOHW-UHFFFAOYSA-N
InChi Code: InChI=1S/C31H38N2O5S/c1-23(2)27-22-33-18-7-6-9-28(33)31(27)39(34,35)26-13-11-25(12-14-26)38-20-8-17-32(3)19-16-24-10-15-29(36-4)30(21-24)37-5/h6-7,9-15,18,21-23H,8,16-17,19-20H2,1-5H3
SMILES Code: CC(C1=CN2C=CC=CC2=C1S(=O)(C3=CC=C(OCCCN(CCC4=CC=C(OC)C(OC)=C4)C)C=C3)=O)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 550.714 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Bellissant E, Giudicelli JF. Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers. Br J Clin Pharmacol. 1999 Dec;48(6):801-10. PubMed PMID: 10594483; PubMed Central PMCID: PMC2014307.
2: Dongay B, Dol-Gleizes F, Herbert JM. Effect of fantofarone, a new Ca2+ channel antagonist, on angioplasty-induced vasospasm in an atherosclerotic rabbit model. Biochem Pharmacol. 1998 Jun 15;55(12):2047-50. PubMed PMID: 9714327.
3: Adovelande J, Delèze J, Schrével J. Synergy between two calcium channel blockers, verapamil and fantofarone (SR33557), in reversing chloroquine resistance in Plasmodium falciparum. Biochem Pharmacol. 1998 Feb 15;55(4):433-40. PubMed PMID: 9514077.
4: Glasser SP, Singh SN, Humen DP. Safety and efficacy of monotherapy with fantofarone, a novel calcium channel antagonist, in patients with chronic stable angina pectoris. Fantofarone Study Group. J Clin Pharmacol. 1997 Jan;37(1):53-7. PubMed PMID: 9048273.
5: Romey G, Lazdunski M. Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels. J Pharmacol Exp Ther. 1994 Dec;271(3):1348-52. PubMed PMID: 7996445.
6: Chatelain P, Matteazzi JR, Laruel R. Interaction of the calcium antagonist fantofarone with phospholipids: electrostatic effects. Biochem Pharmacol. 1994 Oct 7;48(7):1393-8. PubMed PMID: 7945438.
7: Romey G, Bois P, Lazdunski M. Effects of two chemically related new Ca2+ channel antagonists, SR33557 (fantofarone) and SR33805, on the L-type cardiac channel. Eur J Pharmacol. 1994 Sep 22;263(1-2):101-5. PubMed PMID: 7821341.
8: Chatelain P, Matteazzi JR, Laruel R. Binding of fantofarone, a novel Ca2+ antagonist, to serum albumin: a fluorescence study. J Pharm Sci. 1994 May;83(5):674-6. PubMed PMID: 8071819.
9: Barthélémy G, Chatelain P, Manning A. Fantofarone (SR 33557): cardiovascular actions in anesthetized dogs. Arch Int Pharmacodyn Ther. 1994 Mar-Apr;327(2):204-19. PubMed PMID: 7979829.
10: Vander Elst L, Chatelain P, Manning AS, Laruel R, Van Haverbeke Y, Muller RN. 31P nuclear magnetic resonance study of the effects of the calcium ion channel antagonist fantofarone on the rat heart. Eur J Pharmacol. 1994 Jan 14;251(2-3):163-72. PubMed PMID: 8149974.
11: Hodeige D, Chatelain P, Manning A. Fantofarone (SR33557): effects on myocardial oxygen consumption and coronary blood flow. Pharmacology. 1994 Jan;48(1):49-55. PubMed PMID: 8309987.
12: Manning A, Mouton J, Chatelain P. Fantofarone (SR 33557): effect on post-ischaemic functional recovery in perfused rat hearts. Eur J Pharmacol. 1992 Sep 22;220(2-3):249-58. PubMed PMID: 1425996.
